Amgen and Allergan Submit Biosimilar BLA for ABP 215 to U.S. FDA

THOUSAND OAKS, Calif., Nov. 15, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 215, a biosimilar...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news